Artiva Biotherapeutics Announces Upsized $167 Million IPO

San Diego – July 22, 2024 – Cooley advised Artiva Biotherapeutics, a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, on its upsized $167 million initial public offering (IPO).

The IPO was for 13,920,000 shares of common stock at a price to the public of $12 per share, with a 30-day option for the underwriters to purchase up to an additional 2,088,000 shares of common stock at the IPO price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on July 19, 2024, under the symbol ARTV. Jefferies, TD Cowen and Cantor acted as joint book-running managers, and Wedbush PacGrow and Needham & Company acted as co-lead managers for the offering.

Partners Carlos Ramirez and Charlie Kim led the Cooley team advising Artiva.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.